NCT03763123 - A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 24, 2018

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2020

Conditions

Ovarian Cancer

Interventions

DRUG

Sevacizumab

Drug: Sevacizumab escalating doses of Sevacizumab : 0.5mg/kg，1mg/kg，1.5mg/kg and 2mg/kg

DRUG

Paclitaxel

paclitaxel 80mg/m2 as a \> 3-hour IV infusion on days 1, 8,15, and 22 every 4 weeks;

DRUG

Topotecan

topotecan 4 mg/m2 as a \>30 minute IV infusion on days 1, 8, and 15 every 4 weeks ;

Trial Locations (6)

RECRUITING

Beijing Cancer Hospital, Beijing

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

RECRUITING

The first affiliated hospital,sun yat-sen university, Guangzhou

SUSPENDED

the Affiliated Cancer Hospital of Harbin Medical University, Harbin

RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

Wuhan Union Hospital, Wuhan